Dynamic innate immune response determines susceptibility to SARS-CoV-2 infection and early replication kinetics
Open accessPublished version of a preprint
The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Abstract
Initial replication of SARS-CoV-2 in the upper respiratory tract is required to establish infection, and the replication level correlates with the likelihood of viral transmission. Here, we examined the role of host innate immune defenses in restricting early SARS-CoV-2 infection using transcriptomics and biomarker-based tracking in serial patient nasopharyngeal samples and experiments with airway epithelial organoids. SARS-CoV-2 initially replicated exponentially, with a doubling time of ∼6 h, and induced interferon-stimulated genes (ISGs) in the upper respiratory tract, which rose with viral replication and peaked just as viral load began to decline. Rhinovirus infection before SARS-CoV-2 exposure accelerated ISG responses and prevented SARS-CoV-2 replication. Conversely, blocking ISG induction during SARS-CoV-2 infection enhanced viral replication from a low infectious dose. These results show that the activity of ISG-mediated defenses at the time of SARS-CoV-2 exposure impacts infection progression and that the heterologous antiviral response induced by a different virus can protect against SARS-CoV-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure S1. iRegulon analysis of transcription factor–binding sites enriched in RNA from control subjects compared with SARS-CoV-2–positive patients. Related to Fig 1. (A) Transcription factor (TF) motifs/track–binding sites enriched in NP RNA from control subjects. Bars show strength of association (normalized enrichment score [NES]) with motifs/tracks and associated transcription factors. Transcription factors associated with regulation of neuronal tissue–specific genes are highlighted in red. (B and C) Targets of transcription factors REST (B) and POU3F2 (C) enriched in NP RNA from control subjects. Red text indicates targets previously shown to be more highly expressed in olfactory compared with respiratory epithelium. Asterisks indicate transcripts also enriched in olfactory sensory neurons (olfactory epithelium, respiratory epithelium, and olfactory sensory neuron expression data are from Olender et al., 2016).](https://figures.cochat.ai/paper-figures/5437738b2df74031b1ef04c237863203/dynamic-innate-immune-response-determines-susceptibility-to-sars-cov-2-infection-figure-3.jpg)

![Figure S2. Relationship between age or sex and and NP CXCL10 in 140 SARS-CoV-2–positive patients. Related to Fig 2. (A) Age distribution of 140 patients studied. (B) Sex distribution of 140 patients studied. (B) Sex distribution and inpatient/outpatient status of 140 patients studied. (C) Comparison of age in outpatients versus admitted patients. Number of patients shown in parentheses. Groups were compared by unpaired t test, with P value shown. (D) Correlation analysis showing lack of significant correlation between age and NP CXCL10 protein level, based on 140 patients. (E and F) Comparison of NP CXCL10 protein level (E) and viral load (F) based on age and inpatient/outpatient status. No significant differences were detected between groups by unpaired t test. (G and H) Correlation between viral load and NP CXCL10 in all patients (G) and outpatients (H) in all patients or patients segregated by sex. For all patients, according to simple linear regression analysis, the slope of all samples is significantly nonzero (r2 = 0.2030, P < 0.0001), but slopes are not significantly different for each sex. For outpatients only, the slope of the regression line is not significantly nonzero, likely due to lower numbers (male [M] outpatient, n = 18; female [F] outpatient, n = 20).](https://figures.cochat.ai/paper-figures/f83a4b2a8b464401b03922b5e6153e7e/dynamic-innate-immune-response-determines-susceptibility-to-sars-cov-2-infection-figure-5.jpg)








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Previous studies of viral infection using this model considered gene expression in each cell type, but not heterogeneous response patterns, which may be of biological and clinical relevance in understanding the tissue response to respiratory virus infections44,45.”
From Causal identification of single-cell experimental perturbation effects with CINEMA-OT (2023) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As expected, in response to RV infection, most epithelial cell types exhibited robust induction of the interferon response, with upregulation of several interferon-stimulated genes, including ISG15, IFI44, STAT1, MX1, and others (Fig. 4c,d)44.”
From Causal identification of single-cell experimental perturbation effects with CINEMA-OT (2023) · cites this paper as [44]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype
Kim, D., Paggi, J. M., Park, C., Bennett, C., & Salzberg, S. L. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0201-4 · Cited by 15,022
StringTie enables improved reconstruction of a transcriptome from RNA-seq reads
Pertea, M., Pertea, G. M., Antonescu, C. M., Chang, T.-C., Mendell, J. T., & Salzberg, S. L. (2015) · Nature Biotechnology · doi:10.1038/nbt.3122 · Cited by 14,298
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients
Zou, L., Ruan, F., Huang, M., Liang, L., Huang, H., Hong, Z., Yu, J., Kang, M., Song, Y., Xia, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2001737 · Cited by 4,810
Temporal dynamics in viral shedding and transmissibility of COVID-19
He, X., Lau, E. H. Y., Wu, P., Deng, X., Wang, J., Hao, X., Lau, Y. C., Wong, J. Y., Guan, Y., Tan, X., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0869-5 · Cited by 4,247
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., Jordan, T. X., Oishi, K., Panis, M., Sachs, D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.026 · Cited by 4,222
Virus interference. I. the interferon
Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451
Research works printed but not linked: 2
- Banerjee, A.K., M.R. Blanco, E.A. Bruce, D.D. Honson, L.M. Chen, A. Chow, P. Bhat, N. Ollikainen, S.A. Quinodoz, C. Loney,. 2020 b. SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to Suppress Host Defenses. Cell. 183: 1325– 1339.e21. 10.1016/j.cell.2020.10.004 33080218 PMC7543886 · DOI · Paper page
- Centers for Disease Control and Prevention. 2021 a. Emerging SARS-CoV-2 Variants. https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/scientific-brief-emerging-variants.html (accessed January 8, 2021). 34009774
Cited by
Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19
Ziegler, C. G. K., Miao, V. N., Owings, A. H., Navia, A. W., Tang, Y., Bromley, J. D., Lotfy, P., Sloan, M., Laird, H., Williams, H. B., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.023 · Cited by 362
Viral Interference between Respiratory Viruses
Piret, J., & Boivin, G. (2022) · Emerging Infectious Diseases · doi:10.3201/eid2802.211727 · Cited by 302
The interferon landscape along the respiratory tract impacts the severity of COVID-19
Sposito, B., Broggi, A., Pandolfi, L., Crotta, S., Clementi, N., Ferrarese, R., Sisti, S., Criscuolo, E., Spreafico, R., Long, J. M., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.016 · Cited by 269
Innate immune evasion strategies of SARS-CoV-2
Minkoff, J. M., & tenOever, B. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00839-1 · Cited by 244
Mucosal immune response in biology, disease prevention and treatment
Zhou, X., Wu, Y., Zhu, Z., Lu, C., Zhang, C., Zeng, L., Xie, F., Zhang, L., & Zhou, F. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02043-4 · Cited by 186
Natural mucosal barriers and COVID-19 in children
Pierce, C. A., Sy, S., Galen, B., Goldstein, D. Y., Orner, E., Keller, M. J., Herold, K. C., & Herold, B. C. (2021) · JCI Insight · doi:10.1172/jci.insight.148694 · Cited by 165
Pathogenesis of Respiratory Viral and Fungal Coinfections
Salazar, F., Bignell, E., Brown, G. D., Cook, P. C., & Warris, A. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00094-21 · Cited by 178
Human organoid models to study SARS-CoV-2 infection
Han, Y., Yang, L., Lacko, L. A., & Chen, S. (2022) · Nature Methods · doi:10.1038/s41592-022-01453-y · Cited by 163
Intravenous administration of BCG protects mice against lethal SARS-CoV-2 challenge
Hilligan, K. L., Namasivayam, S., Clancy, C. S., O’Mard, D., Oland, S. D., Robertson, S. J., Baker, P. J., Castro, E., Garza, N. L., Lafont, B. A. P., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20211862 · Cited by 136
Hatton, C. F., Botting, R. A., Dueñas, M. E., Haq, I., Verdon, B., Thompson, B. J., Spegarova, J. S., Gothe, F., Stephenson, E., Gardner, A. I., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27318-0 · Cited by 133
SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic
Bertoletti, A., Bert, N. L., & Tan, A. T. (2022) · Immunity · doi:10.1016/j.immuni.2022.08.008 · Cited by 126
Understanding Rhinovirus Circulation and Impact on Illness
Esneau, C., Duff, A. C., & Bartlett, N. W. (2022) · Viruses · doi:10.3390/v14010141 · Cited by 123
Changing patterns of infectious diseases in children during the COVID-19 pandemic
Yang, M., Su, Y., Chen, P.-H., Tsai, C., Lin, T.-I., & Wu, J. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1200617 · Cited by 109
Causal identification of single-cell experimental perturbation effects with CINEMA-OT
Dong, M., Wang, B., Wei, J., de O. Fonseca, A. H., Perry, C. J., Frey, A., Ouerghi, F., Foxman, E. F., Ishizuka, J. J., Dhodapkar, R. M., et al. (2023) · Nature Methods · doi:10.1038/s41592-023-02040-5 · Cited by 94
“In order to demonstrate CINEMA-OT’s ability to perform single-cell level experimental perturbation analysis, we have applied CINEMA-OT to newly-collected scRNA-seq data of rhinovirus infection in primary human airway organoids [37] (Figure 4A).”
Self-citationDuncan, C. J. A., Skouboe, M. K., Howarth, S., Hollensen, A. K., Chen, R., Børresen, M. L., Thompson, B. J., Spegarova, J. S., Hatton, C. F., Stæger, F. F., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20212427 · Cited by 97
Coinfection by influenza A virus and respiratory syncytial virus produces hybrid virus particles
Haney, J., Víjayakríshnan, S., Streetley, J., Dee, K., Goldfarb, D., Clarke, M., Mullin, M., Carter, S. D., Bhella, D., & Murcia, P. R. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01242-5 · Cited by 90
Evolution of enhanced innate immune suppression by SARS-CoV-2 Omicron subvariants
Reuschl, A., Thorne, L., Whelan, M. V. X., Ragazzini, R., Furnon, W., Cowton, V. M., Lorenzo, G. D., Mesner, D., Turner, J. L. E., Dowgier, G., et al. (2024) · Nature Microbiology · doi:10.1038/s41564-023-01588-4 · Cited by 87
PLSCR1 is a cell-autonomous defence factor against SARS-CoV-2 infection
Xu, D., Jiang, W., Wu, L., Gaudet, R. G., Park, E., Su, M., Cheppali, S. K., Cheemarla, N. R., Kumar, P., Uchil, P. D., et al. (2023) · Nature · doi:10.1038/s41586-023-06322-y · Cited by 99
Self-citationKoerber, N., Priller, A., Yazici, S., Bauer, T., Cheng, C., Mijočević, H., Wintersteller, H., Jeske, S. D., Vogel, E., Feuerherd, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27649-y · Cited by 78
Zhu, F., Huang, S., Liu, X., Chen, Q., Zhuang, C., Zhao, H. J., Han, J., Jaen, A. M., Do, T. H., Peter, J., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00349-1 · Cited by 76
Zhuang, X., Tsukuda, S., Wrensch, F., Wing, P. A. C., Schilling, M., Harris, J. M., Borrmann, H., Morgan, S. B., Cane, J., Mailly, L., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103144 · Cited by 65
Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines
Fraser, R., Resendiz, A. O., Mazein, A., & Dockrell, D. H. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.01.003 · Cited by 65
Johansen, M. D., Mahbub, R. M., Idrees, S., Nguyen, D. H., Miemczyk, S., Pathinayake, P. S., Nichol, K., Hansbro, N. G., Gearing, L. J., Hertzog, P. J., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202108-1901oc · Cited by 63
ACTIV-3/TICO Study Group, Rogers, A. J., Wentworth, D. N., Phillips, A. N., Shaw‐Saliba, K., Dewar, R. L., Aggarwal, N. R., Babiker, A. G., Chang, W., Dharan, N. J., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m22-0924 · Cited by 60
Dee, K., Schultz, V., Haney, J., Bissett, L. A., Magill, C., & Murcia, P. R. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac494 · Cited by 57
Otter, C. J., Fausto, A., Tan, L. H., Khosla, A. S., Cohen, N. A., & Weiss, S. R. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2218083120 · Cited by 63
Fage, C., Hénaut, M., Carbonneau, J., Piret, J., & Boivin, G. (2022) · Viruses · doi:10.3390/v14020395 · Cited by 60
Interfering with SARS-CoV-2: are interferons friends or foes in COVID-19?
Zanoni, I. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.08.004 · Cited by 50
SARS-CoV-2 escapes direct NK cell killing through Nsp1-mediated downregulation of ligands for NKG2D
Lee, M. J., Leong, M. W., Rustagi, A., Beck, A., Zeng, L., Holmes, S., Qi, L., & Blish, C. (2022) · bioRxiv · doi:10.1016/j.celrep.2022.111892 · Cited by 31
Distinct airway epithelial immune responses after infection with SARS-CoV-2 compared to H1N1
Stölting, H., Baillon, L., Frise, R., Bonner, K., Hewitt, R. J., Molyneaux, P. L., Gore, M. L., Barclay, W., Saglani, S., & Lloyd, C. M. (2022) · Mucosal Immunology · doi:10.1038/s41385-022-00545-4 · Cited by 45
Protective immune trajectories in early viral containment of non-pneumonic SARS-CoV-2 infection
Pekayvaz, K., Leunig, A., Kaiser, R. W. J., Joppich, M., Brambs, S., Janjic, A., Popp, O., Nixdorf, D., Fumagalli, V., Schmidt, N., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28508-0 · Cited by 39
Pizzorno, A., Padey, B., Dulière, V., Mouton, W., Oliva, J., Laurent, E., Milesi, C., Lina, B., Traversier, A., Julien, T., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac357 · Cited by 40
Rand, U., Kupke, S. Y., Shkarlet, H., Hein, M. D., Hirsch, T., Marichal‐Gallardo, P., Čičin‐Šain, L., Reichl, U., & Bruder, D. (2021) · Cells · doi:10.3390/cells10071756 · Cited by 46
Zheng, Q., Wang, D., Lin, R., Lv, Q., & Wang, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1013322 · Cited by 42
Rando, H. M., MacLean, A. L., Lee, A. J., Lordan, R., Ray, S., Bansal, V., Skelly, A. N., Sell, E., Dziak, J. J., Shinholster, L., et al. (2021) · mSystems · doi:10.1128/msystems.00095-21 · Cited by 49
New insights into the pathogenesis of SARS-CoV-2 during and after the COVID-19 pandemic
Carvajal, J. J., García-Castillo, V., Cuellar, S. V., Campillay-Véliz, C. P., Salazar‐Ardiles, C., Avellaneda, A. M., Muñoz, C. A., Retamal-Díaz, A. R., Bueno, S. M., González, P. A., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1363572 · Cited by 51
Cheemarla, N. R., Hanron, A. E., Fauver, J. R., Bishai, J. D., Watkins, T. A., Brito, A. F., Zhao, D., Alpert, T., Vogels, C. B. F., Ko, A. I., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00296-8 · Cited by 37
Self-citationLow baseline IFN-γ response could predict hospitalization in COVID-19 patients
Crémoni, M., Allouche, J., Graça, D., Zorzi, K., Fernandez, C., Teisseyre, M., Benzaken, S., Ruetsch-Chelli, C., Esnault, V. L. M., Dellamonica, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.953502 · Cited by 46
Comparison by Age of the Local Interferon Response to SARS-CoV-2 Suggests a Role for IFN-ε and -ω
Pierangeli, A., Gentile, M., Oliveto, G., Frasca, F., Sorrentino, L., Matera, L., Nenna, R., Viscido, A., Fracella, M., Petrarca, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.873232 · Cited by 41
The kinetics of SARS-CoV-2 infection based on a human challenge study
Iyaniwura, S. A., Ribeiro, R. M., Zitzmann, C., Phan, T., Ke, R., & Perelson, A. S. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2406303121 · Cited by 42
Plasmacytoid dendritic cells during COVID-19: Ally or adversary?
van der Sluis, R. M., Holm, C. K., & Jakobsen, M. R. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111148 · Cited by 38
Hemin as a novel candidate for treating COVID-19 via heme oxygenase-1 induction
Kim, D., Ahn, H., Go, H., Kim, D.-Y., Kim, J., Lee, J., Park, S., Song, C., Lee, S., Ha, S.-D., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-01054-3 · Cited by 32
Variable susceptibility of intestinal organoid–derived monolayers to SARS-CoV-2 infection
Jang, K. K., Kaczmarek, M. E., Dallari, S., Chen, Y.-H., Tada, T., Axelrad, J. E., Landau, N. R., Stapleford, K. A., & Cadwell, K. (2022) · PLoS Biology · doi:10.1371/journal.pbio.3001592 · Cited by 37
Cheemarla, N. R., Watkins, T. A., Mihaylova, V. T., & Foxman, E. F. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad402 · Cited by 40
Self-citationZhang, Y., Bharathi, V., Dokoshi, T., de Anda, J., Ursery, L., Kulkarni, N. N., Nakamura, Y., Chen, J., Luo, E. W.-C., Wang, L., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2300644120 · Cited by 40
An intranasal nanoparticle STING agonist protects against respiratory viruses in animal models
Leekha, A., Saeedi, A., Kumar, M., Sefat, K. M. S. R., Martinez-Paniagua, M. A., Meng, H., Fathi, M., Kulkarni, R. S., Reichel, K., Biswas, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50234-y · Cited by 36
Vanderwall, E. R., Barrow, K. A., Rich, L. M., Read, D. F., Trapnell, C., Okoloko, O., Ziegler, S. F., Hallstrand, T. S., White, M. P., & Debley, J. S. (2022) · Scientific Reports · doi:10.1038/s41598-022-10763-2 · Cited by 32
Sohn, S.-Y., Hearing, J., Mugavero, J., Kirillov, V., Gorbunova, E., Helminiak, L., Mishra, S., Mackow, E. R., Hearing, P., Reich, N. C., et al. (2021) · mBio · doi:10.1128/mbio.02756-21 · Cited by 28
3D Human Organoids: The Next “Viral” Model for the Molecular Basis of Infectious Diseases
Chia, S. P. S., Kong, S. L. Y., Pang, J. K. S., & Soh, B.-S. (2022) · Biomedicines · doi:10.3390/biomedicines10071541 · Cited by 29
Devadoss, D., Acharya, A., Manevski, M., Houserova, D., Cioffi, M. D., Pandey, K., Nair, M. G., Chapagain, P. P., Mirsaeidi, M. S., Borchert, G. M., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104685 · Cited by 26
Grebennikov, D. S., Васильевна, К. А., Loguinova, M. Y., Casella, V., Meyerhans, A., & Bocharov, G. A. (2022) · Mathematics · doi:10.3390/math10173154 · Cited by 28
Respiratory viral coinfections: interactions, mechanisms and clinical implications
Deol, P., & Miura, T. A. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01225-3 · Cited by 29
Organoid Studies in COVID-19 Research
Kim, J., Koo, B., & Clevers, H. C. (2022) · International Journal of Stem Cells · doi:10.15283/ijsc21251 · Cited by 28
Lack of association between pandemic chilblains and SARS-CoV-2 infection
Gehlhausen, J. R., Little, A. J., Ko, C. J., Emmenegger, M., Lucas, C. G. D. O., Wong, P., Klein, J., Lu, P., Mao, T., Jaycox, J. R., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2122090119 · Cited by 25
Ramasamy, R. (2022) · Viruses · doi:10.3390/v14050933 · Cited by 27
Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines
Zhu, C., Pang, S., Liu, J., & Duan, Q. (2024) · Drugs · doi:10.1007/s40265-024-02013-8 · Cited by 28
SARS-CoV-2 variants of concern and vaccine escape, from Alpha to Omicron and beyond
Ong, S. W. X., Chia, T. R. T., & Young, B. E. (2022) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2022.2057299 · Cited by 25
Use of oral polio vaccine and the incidence of COVID-19 in the world
Habibzadeh, F., Chumakov, K., Sajadi, M. M., Yadollahie, M., Stafford, K. A., Simi, A., Kottilil, S., Hafizi-Rastani, I., & Gallo, R. C. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265562 · Cited by 22
SARS-CoV-2 Point Mutation and Deletion Spectra and Their Association with Different Disease Outcomes
Martínez‐González, B., Soria, M. E., Vázquez-Sirvent, L., Ferrer‐Orta, C., Lobo-Vega, R., Mínguez, P., de la Fuente, L., Lloréns, C., Soriano, B., Ramos, R., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00221-22 · Cited by 25
Priming With Rhinovirus Protects Mice Against a Lethal Pulmonary Coronavirus Infection
Cox, G., Gonzalez, A. J., Ijezie, E. C., Rodriguez, A., Miller, C. R., Leuven, J. T. V., & Miura, T. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.886611 · Cited by 22
Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses
Klasse, P. J., & Moore, J. P. (2022) · Journal of Virology · doi:10.1128/jvi.00034-22 · Cited by 25
Coronaviral Infection and Interferon Response: The Virus-Host Arms Race and COVID-19
Liu, Q., Chi, S., Dmytruk, K. V., Dmytruk, O. V., & Tan, S. (2022) · Viruses · doi:10.3390/v14071349 · Cited by 26
Risk of severe COVID-19 infection among adults with prior exposure to children
Solomon, M. D., Escobar, G. J., Lu, Y., Schlessinger, D., Steinman, J. B., Steinman, L., Lee, C., & Liu, V. X. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204141119 · Cited by 22
Immune–epithelial cell cross‐talk enhances antiviral responsiveness to SARS‐CoV‐2 in children
Magalhães, V. G., Lukassen, S., Drechsler, M., Loske, J., Burkart, S. S., Wüst, S., Jacobsen, E., Roehmel, J. F., Mall, M. A., Debatin, K., et al. (2023) · EMBO Reports · doi:10.15252/embr.202357912 · Cited by 21
Doxey, A. C., Mazen, N. A., Homm, M., Chu, V., Hunjan, M. S., Lobb, B., Lee, S., Kurs‐Lasky, M., Williams, J. V., MacDonald, W., et al. (2025) · Genome Medicine · doi:10.1186/s13073-025-01447-3 · Cited by 27
High burden of viruses and bacterial pathobionts drives heightened nasal innate immunity in children
Watkins, T. A., Green, A. B., Amat, J. A. R., Cheemarla, N. R., Hänsel, K., Lozano, R. J., Dudgeon, S. N., Germain, G., Landry, M. L., Schulz, W. L., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20230911 · Cited by 22
Self-citationHan, M., Breckenridge, H. A., Kuo, S., Singh, S., Goldsmith, A. M., Li, Y., Kreger, J. E., Bentley, J. K., & Hershenson, M. B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.952509 · Cited by 19
Effects of COVID-19 and Social Distancing on Rhinovirus Infections and Asthma Exacerbations
Kreger, J. E., & Hershenson, M. B. (2022) · Viruses · doi:10.3390/v14112340 · Cited by 20
Considerations for viral co-infection studies in human populations
Chin, T., Foxman, E. F., Watkins, T. A., & Lipsitch, M. (2024) · mBio · doi:10.1128/mbio.00658-24 · Cited by 22
Self-citationTransient anti-interferon autoantibodies in the airways are associated with recovery from COVID-19
Babcock, B. R., Kosters, A., Eddins, D. J., Donaire, M. S., Sarvadhavabhatla, S., Pae, V., Beltran, F., Murray, V., Gill, G., Xie, G., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adq1789 · Cited by 19
Oo, A., Zandi, K., Shepard, C., Bassit, L., Musall, K., Goh, S. L., Cho, Y., Kim, D., Schinazi, R. F., & Kim, B. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101635 · Cited by 19
Baker, P. J., Bohrer, A. C., Castro, E., Amaral, E. P., Snow-Smith, M., Torres-Juárez, F., Gould, S. T., Queiroz, A. T. L., Fukutani, E. R., Jordan, C. M., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adp7951 · Cited by 19
Tao, K. P., Chong, K. C., Chan, K. Y. Y., Pun, J. C. S., Tsun, J. G., Chow, S., Ng, C. S. H., Wang, M. H., Chan, P. K. S., Li, A. M., et al. (2022) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2022.100147 · Cited by 25
Can live-attenuated SARS-CoV-2 vaccine contribute to stopping the pandemic?
Tang, P. C. H., Ng, W. H., King, N. J. C., & Mahalingam, S. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010821 · Cited by 19
Clash of the titans: interferons and SARS-CoV-2
Jouvenet, N., Goujon, C., & Banerjee, A. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.10.009 · Cited by 19
Executable network of SARS-CoV-2-host interaction predicts drug combination treatments
Howell, R. S. M., Clarke, M. A., Reuschl, A., Chen, T., Abbott-Imboden, S., Singer, M., Lowe, D. M., Bennett, C. L., Chain, B., Jolly, C. L., et al. (2022) · npj Digital Medicine · doi:10.1038/s41746-022-00561-5 · Cited by 18
Duncan, J. K. S., Xu, D., Licursi, M., Joyce, M., Saffran, H. A., Liu, K., Gohda, J., Tyrrell, D. L., Kawaguchi, Y., & Hirasawa, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.930086 · Cited by 20
Burstein, R., Althouse, B. M., Adler, A., Akullian, A. N., Brandstetter, E., Cho, S., Emanuels, A., Fay, K. A., Gamboa, L., Han, P. D., et al. (2022) · medRxiv · doi:10.1101/2022.02.04.22270474 · Cited by 16
Lee, J. S., Dittmar, M., Miller, J., Li, M., Ayyanathan, K., Ferretti, M., Hulahan, J., Whig, K., Etwebi, Z., Griesman, T., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.115115 · Cited by 23
Englmeier, L., & Subburayalu, J. (2022) · Immunity & Ageing · doi:10.1186/s12979-022-00262-3 · Cited by 17
Jarju, S., Wenlock, R. D., Danso, M., Jobe, D., Jagne, Y. J., Darboe, A., Kumado, M., Jallow, Y., Touray, M., Ceesay, E. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48098-3 · Cited by 16
Liu, G., & Gack, M. U. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102252 · Cited by 20
Resnick, J. D., Beer, M., & Pekosz, A. S. (2023) · Pathogens · doi:10.3390/pathogens12030480 · Cited by 13
Impact of COVID‐19 on Respiratory Virus Infections in Children, Japan, 2018–2023
Takashita, E., Shimizu, K., Kawakami, C., Momoki, T. S., Saikusa, M., Ozawa, H., Kumazaki, M., Usuku, S., Tanaka, N., Senda, R., et al. (2025) · Immunity Inflammation and Disease · doi:10.1002/iid3.70176 · Cited by 12
Lim, F. Y., Lea, H. G., Dostie, A. M., Kim, S.-Y., van Neel, T. L., Hassan, G. W., Takezawa, M. G., Starita, L. M., Adams, K. N., Boeckh, M., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2024.105531 · Cited by 15
Age-associated differences in mucosal and systemic host responses to SARS-CoV-2 infection
Hurst, J. H., Mohan, A. A., Dalapati, T., George, I. A., Aquino, J. N., Lugo, D. J., Pfeiffer, T. S., Rodriguez, J., Rotta, A. T., Turner, N., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57655-3 · Cited by 20
Modeling Innate Antiviral Immunity in Physiological Context
Goldstein, M. E., & Scull, M. A. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167374 · Cited by 14
SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise
Duerr, R., Crosse, K. M., Valero-Jimenez, A. M., & Dittmann, M. (2021) · Microorganisms · doi:10.3390/microorganisms9071389 · Cited by 13
The Common Cold Is Associated With Protection From SARS-CoV-2 Infections
Moore, C. M., Secor, E. A., Everman, J. L., Fairbanks-Mahnke, A., Jackson, N. D., Pruesse, E., Diener, K., Morin, A., Arbes, S. J., Bacharier, L. B., et al. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf374 · Cited by 12
The early interferon catches the SARS-CoV-2
Decker, T. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20211667 · Cited by 12
Hussein, H. A. M., Thabet, A. A., Mohamed, T. I. A., Elnosary, M. E., Sobhy, A., El-Adly, A. M., Wardany, A. A., Bakhiet, E. K., Afifi, M. M., Abdul-Raouf, U. M., et al. (2023) · Central European Journal of Immunology · doi:10.5114/ceji.2023.129981 · Cited by 10
Sajjadi, S., Hejazi, S., Ravanshad, S., & Esfehani, R. J. (2022) · Gene · doi:10.1016/j.gene.2022.146550 · Cited by 11
Mushebenge, A. G.-A., Ugbaja, S. C., Mtambo, S. E., Ntombela, T., Metu, J. I., Babayemi, O., Chima, J. I., Appiah‐Kubi, P., Odugbemi, A. I., Ntuli, M. L., et al. (2023) · Molecules · doi:10.3390/molecules28062641 · Cited by 10
Reuss, D., Brown, J. C., Sukhova, K., Furnon, W., Cowton, V. M., Patel, A. H., Palmarini, M., Thompson, C., & Barclay, W. (2025) · Virology · doi:10.1016/j.virol.2025.110556 · Cited by 9
Huijghebaert, S., Parviz, S., Rabago, D., Baxter, A. L., Chatterjee, U. S., Khan, F. R., Fabbris, C., Poulas, K. A., & Hsu, S. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1161881 · Cited by 13
Marjaneh, M. M., Challenger, J. D., Salas, A., Gómez‐Carballa, A., Sivananthan, A., Calle, I. R., Barbeito‐Castiñeiras, G., Foo, C. Y., Wu, Y., Liew, F., et al. (2023) · Journal of Infection · doi:10.1016/j.jinf.2023.10.009 · Cited by 11
Zhang, Q., & Friedman, P. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010963 · Cited by 14
SARS-CoV-2 Infection in Patients with Cystic Fibrosis: What We Know So Far
Biondo, C., Midiri, A., Gerace, E., Zummo, S., & Mancuso, G. (2022) · Life · doi:10.3390/life12122087 · Cited by 11
Circulation of respiratory viruses during the COVID-19 pandemic in The Gambia
Jarju, S., Senghore, E., Brotherton, H., Saidykhan, A., Jallow, S., Krubally, E., Sinjanka, E., Ndene, M. N., Bajo, F., Sanyang, M. M., et al. (2022) · Gates Open Research · doi:10.12688/gatesopenres.14155.1 · Cited by 9
Keenum, M. C., Chatterjee, P., Atalis, A., Pandey, B., Jimenez, A. C., & Roy, K. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2023.122097 · Cited by 12
Metadata
- Authors
- Cheemarla, N. R., Watkins, T. A., Mihaylova, V. T., Wang, B., Zhao, D., Wang, G., Landry, M. L., & Foxman, E. F.
- Affiliations
- Yale University (US)
- Corresponding author
- Foxman, Ellen F.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2021-06-15
- Volume
- 218
- Issue
- 8
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC8210587
- OpenAlex
- W3169110632
- Cited by
- 213
- References
- 101
- Citations by year
- 2026: 20 · 2025: 31 · 2024: 36 · 2023: 39 · 2022: 65 · 2021: 22
- FWCI
- 12.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (submittedVersion, cc-by-nc-nd)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- Funders
- George Mason University
- Yale
- China Scholarship Council
- Gruber Foundation
- National Institutes of Health (T32AI007019)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, innate immunity, interferon-stimulated genes, viral replication kinetics, upper respiratory tract, rhinovirus, nasopharyngeal viral load, infection susceptibility, virus transmission
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.